We are a pharmaceutical company specialized in the comercialization of exclusive medicines, innovative and orphan drugs.
We develop and implement market strategies to guarantee access to all patients to the most effective therapies and best treatments.
We believe in the fundamental values of integrity, ethics and social commitment.
We want to be recognized as an international partner, attentive to the needs of patients and health professionals, completely dedicated to proposing effective solutions through innovation, quality and competence.
We offer high standards of services at all times that improve patients’ lives through a large portfolio of low-cost medicines, with particular attention to rare diseases.
We are a young and dynamic pharmaceutical company which, through the coordination of an international team of highly qualified, competent and motivated professionals and partners, captures the full potential and evolution of the market to successfully commercialize medicinal specialties, innovative drugs and orphan drugs.
we manage our business in full transparency, fairness and loyalty to customers, suppliers and healthcare professionals.
we deeply know the market and we use our experience for the success of the products.
we have excellent cross-functional skills in commercial operations, medical affairs and market access and a solid infrastructure and local presence with a patient-centered approach.
Avas Pharmaceuticals is focused on the commercialization of a wide portfolio of specialties, niche hospital and orphan products to respond to unmet medical needs.
K
MIO
MIO
*2023 data
Partnerships and alliances are a key component of our fast commercial growth strategy: we are focused on creating international collaborations with pharmaceutical and bio-pharmaceutical companies with the aim of facilitating access to innovative therapies for patients.
With our significant experience in various partnership models we are open to both traditional in-licensing solutions but above all to innovative solutions agreed with our potential partner according to its medium and long-term strategic objectives.
Planning and execution of the marketing plan, business intelligence, key accout management, hospital tenders
Extensive experience in pharmaceuticals and rare disease at national, regional and local level; long track record of negotiation skills with country health authority
High competence in medical affairs, MSLs and scientific support to health professionals, medical information
Customer service and validation, risk analysis and assessment, logistics and distribution
We create customised solutions effectively and with a target of excellence.
We provide direct, transparent and constant communication and reports.
We create long-term and trusting relationships with our partners an clients.
For any kind of information you can contact us through the web form.
AVAS Pharmaceuticals is actively involved in pharmacovigilance, gathering reports of adverse effects of pharmaceutical products.
The aim of pharmacovigilance is to collect information and evidence on readily available drugs, so data about the safety of a drug, the relationship between risk and benefit and its adverse effects is always up-to-date, ensuring patient safety.
AVAS Pharmaceuticals provides an email address and mobile phone number which can be used to report any problems with adverse drug reactions.
QPPV: Dr. Viola Di Marco
Hourly availability 24H Phone: +39 333 733 6518
QPPV Deputy: Dr. Fabiana Auricchio
Hourly availability 24H Phone: +39 3351258534
Ai sensi dell’art. 1 comma 125-bis, della Legge 04/08/2017 n. 124, in ottemperanza all’obbligo di trasparenza si segnala che la società è stata destinataria nel corso dell’esercizio sociale chiuso al 31/12/2020 di sovvenzioni, sussidi, vantaggi, contributi o aiuti pubblici in denaro o in natura, non aventi carattere generale, che vengono dettagliati nella tabella in allegato.
Inoltre la società ha ricevuto nel corso dell’esercizio sociale chiuso al 31/12/2020 Aiuti di Stato di cui all’art. 52 Legge n. 234/2012 oggetto di obbligo di pubblicazione nel Registro Nazionale Aiuti di Stato ed ivi indicato nella sezione trasparenza a cui si rinvia.
